At the Boulder Software Club seminar earlier this week a common question was once again raised…how is it that a meaningful ROI may be calculated for a given blog? Well I am not going to address that one here rather I would like to bring to your attention something rather cool I have stumbled upon. [...]

• 69View 3 Comments...http://clsdf.com/2006/02/arriving-at-blog-roi-and-valuation/Arriving+at+Blog+ROI+and+Valuation2006-02-24+08%3A29%3A00admin

The US Patent Office (USPTO) recently issued patent number 7,000,000. It has taken seventy-five years to go from patent number 1 to number 1,000,000 while it has taken less than one-tenth of the time to go from number 6,000,000 to number 7,000,000. Without a doubt the USPTO is swamped and without sufficient resources to process [...]

• 68http://clsdf.com/2006/02/patent-issuance-not-novel-and-non-obvious/Patent+Issuance%3A+Not+Novel+and+Non-obvious2006-02-23+15%3A49%3A00admin

Louisville based RxKinetix, Inc. must be beaming these days. Since announcing the successful conclusion of its Phase II trial for Oral Mucositis (RK-0202) they received a grant through the Grand Challenges in Global Health Initiative (supported by the Bill & Melinda Gates Foundation, NIH, Wellcome Trust, and the Canadian Institutes of Health Research) for the [...]

• 67http://clsdf.com/2006/02/good-data-good-for-local-real-estate/Good+Data+Good+for+Local+Real+Estate2006-02-21+16%3A03%3A00admin

On a day when Kleiner Perkins announces a new $200 million Pandemic and Bio-Defense fund aimed at speeding up worldwide pandemic preparedness, targeting the spread of avian flu, among other diseases, I am also reminded of what appears to be an unusually high concentration of Necrotizing Fascittis and Myositis, or flesh eating disease for short, [...]

• 66View 1 Comment...http://clsdf.com/2006/02/colorado-strep-a-and-necrotizing-fasciitis/Colorado%2C+Strep+A%2C+and+Necrotizing+Fasciitis2006-02-17+01%3A16%3A00admin

I do not normally swipe someone else’s post (thank you Brad) however, this info is to good not to pass along. FYI no start time appears to be provided, I am looking into that and will post as soon as it is confirmed. If you are in Boulder on February 21st and interested in blogging [...]

• 65View 1 Comment...http://clsdf.com/2006/02/boulder-software-club-blogging-and-rss/Boulder+Software+Club%3A+Blogging+and+RSS2006-02-16+04%3A00%3A00admin

Replidyne, Inc., and Forest Laboratories, Inc. (NYSE: FRX) announced that the two companies have entered into an agreement for the commercialization, development and distribution of Replidyne’s new oral antibiotic, faropenem medoxomil, in the United States. Under the terms of the agreement, Forest will make a $50 million upfront payment to Replidyne as well as potential [...]

• 64http://clsdf.com/2006/02/replidyne-forest-labs-reach-agreement/Replidyne+%26amp%3B+Forest+Labs+Reach+Agreement2006-02-14+18%3A08%3A00admin

Another incredible asset in the Colorado life science portfolio is the National Jewish Medical & Research Center. National Jewish has been named the #1 respiratory hospital in America by U.S. News & World Report for eight consecutive years and is rated one of the 25 most influential research institutions in the world in its major [...]

• 63http://clsdf.com/2006/02/check-out-national-jewish-mrc/Check+Out+National+Jewish+M%26amp%3BRC2006-02-14+17%3A34%3A00admin

I am building a spreadsheet to demonstrate the effect that dilution has on an early investor (angel, seed etc.) and the subsequent effect of certain anti-dilution measures that early investors may employ to keep from getting wiped out in later financings. If anyone has such an .xls built already I would love to exchange documents [...]

• 62http://clsdf.com/2006/02/xls-anyone/.xls+Anyone%3F2006-02-13+16%3A10%3A00admin

A historical drop in U.S. cancer deaths was recently reported by the American Cancer Society (ACS). The most recent data demonstrated a drop in cancer related deaths in 2003 relative to 2002. Specifically, cancer killed 556,902 Americans in 2003, down from 557,271 a year earlier. 2006 Cancer Projections: The ACS project that in 2006 approximately [...]

• 61http://clsdf.com/2006/02/turning-point-in-the-fight-against-cancer/Turning+Point+in+the+Fight+Against+Cancer%3F2006-02-10+17%3A39%3A00admin

So regular readers of this blog may recall that I very recently posted on RNA & RNAi and its place in Colorado’s bio history. Well a nice piece was published today on The Motley Fool.com titled RNA: Rule Breaker Nucleic Acid. Not only does Jason Gurn do an admirable job of detailing some complex subject [...]

• 60http://clsdf.com/2006/02/i-love-when-this-happens/I+Love+When+This+Happens2006-02-10+00%3A06%3A00admin

Proof of the growth in Colorado life sciences may in part be benchmarked by quantifying ‘who is noticing us’. Well Colorado bio has found its way on to the radar of Burrill & Company, perhaps the premier life science merchant bank, located in San Francisco (learn more about Burrill & Company here). G. Steven Burrill, [...]

• 59http://clsdf.com/2006/02/colorado-bio-on-the-radar/Colorado+Bio%3A+On+the+Radar2006-02-08+15%3A22%3A00admin

Countdown to VC in the Rockies is on. Don’t miss out, February 22nd to 24th at the Ritz-Carlton Bachelor Gulch, Beaver Creek (Vail), Colorado. Companies who have presented at this conference have raised over $3 billion in the last five years. Here is a list of this years presenting companies. Thanks to the Colorado Venture [...]

• 58http://clsdf.com/2006/02/speaking-of-deal-flow%e2%80%a6/Speaking+of+Deal+Flow%E2%80%A62006-02-07+15%3A30%3A00admin

Myogen, Inc. (Nasdaq: MYOG) has sold its wholly-owned European subsidiary Myogen GmbH for $6.1 million to Wulfing Holding GmbH. The deal centers around a sublicense for rights to Perfan® I.V. (intravenous enoximone) in markets outside North America, from which the former parent will continue to receive a royalty on future net sales. Shedding this particular [...]

• 57http://clsdf.com/2006/02/myogen-getting-lean-and-mean/Myogen+Getting+Lean+and+Mean2006-02-03+15%3A05%3A00admin